Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LH21
Cat. No.:
OB0425LY-074
Appearance:
Solid
Purity:
99.83%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
LH21 is a high-quality neutral cannabinoid CB1 receptor antagonist and related to weight management.
Synonyms:
611207-11-5; LH 21; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1,2,4-triazole; LH-21; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole
CAS No.:
611207-11-5
Compound CID:
10136173
Formula:
C20H20Cl3N3
Formula Weight:
408.75
Specification
Target:
Cannabinoid receptor
Pathway:
GPCR/G protein; Neuronal signaling
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
LH21 can be used to reduce food intake and body weight gain in obese Zucker rats.
